ABOUT THE RESEARCHER

OVERVIEW

Stephan Voss' principal research interest is in developing novel tools to more specifically image malignant disease. The goal of his work, using neuroblastoma both as a laboratory research and clinical model, is to develop neuroblastoma-specific imaging tools that permit pediatric radiologists to image the childhood malignancy with greater sensitivity and specificity. He is the chair of the Imaging section for the multi-center, NCI-sponsored Children's Oncology Group Phase I Consortium.

Research in the Voss laboratory is aimed at developing an animal model for neuroblastoma that can be readily imaged using either a small bore animal magnet, or small animal nuclear medicine cameras.

Voss and colleagues are developing and testing targeted contrast agents, using single chain antibodies derived from intact antibodies with reactivity against neuroblastoma. The single chain antibody (sFv) work involves a team of investigators directed at creating NB- specific, high sensitivity contrast agents by covalently conjugating small tumor targeting antibody fragments (sFv) to nuclear medicine agents, which include both conventional SPECT agents such as 99mTc and novel PET agents such as 64Cu.

In addition to these basic research pursuits, Voss' group is working pediatric oncologists to develop a more systematic assessment of the optimal imaging strategy for diagnosis and follow-up imaging in children with various cancers.

BACKGROUND

Stephan Voss received his MD degree from the University of Wisconsin. He completed an internship at New England Deconess Hospital, a residency at Beth Israel Deaconess Medical Center and a fellowship at Boston Children's Hospital.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Juvenile Granulosa Cell Tumor as the Presenting Feature of McCune-Albright Syndrome. J Endocr Soc. 2021 Sep 01; 5(9):bvab098. View abstract
  2. Response to Febo-Rodriguez et al. Am J Gastroenterol. 2021 07 01; 116(7):1553. View abstract
  3. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 01; 27(13):3543-3548. View abstract
  4. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 11; 115(11):1830-1839. View abstract
  5. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 Aug 19. View abstract
  6. Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL) group. Pediatr Blood Cancer. 2020 09; 67(9):e28361. View abstract
  7. Neck CT angiography examinations for pediatric oropharyngeal trauma: diagnostic yield and proposal of a new targeted technique. Pediatr Radiol. 2020 10; 50(11):1602-1609. View abstract
  8. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View abstract
  9. Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL). Pediatr Blood Cancer. 2020 08; 67(8):e28365. View abstract
  10. Normative database of spatiotemporal gait parameters using inertial sensors in typically developing children and young adults. Gait Posture. 2020 07; 80:206-213. View abstract
  11. Definition of cortical bone involvement in the staging of newly diagnosed pediatric Hodgkin lymphoma: A report from the International Working Group on Staging Evaluation and Response Criteria Harmonization (SEARCH). Pediatr Blood Cancer. 2020 04; 67(4):e28142. View abstract
  12. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clin Cancer Res. 2020 03 15; 26(6):1213-1219. View abstract
  13. Functional and anatomical imaging in pediatric oncology: which is best for which tumors. Pediatr Radiol. 2019 10; 49(11):1534-1544. View abstract
  14. Surveillance imaging in pediatric lymphoma. Pediatr Radiol. 2019 10; 49(11):1565-1573. View abstract
  15. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View abstract
  16. Impact of a Two-Filter Cerebral Embolic Protection Device on the Complexity and Risk of Transcatheter Aortic Valve Replacement. Thorac Cardiovasc Surg. 2020 10; 68(7):616-622. View abstract
  17. Multicenter pre-operative assessment of pediatric ovarian malignancy. J Pediatr Surg. 2019 Sep; 54(9):1921-1925. View abstract
  18. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238. View abstract
  19. Staging and following common pediatric malignancies: MRI versus CT versus functional imaging. Pediatr Radiol. 2018 08; 48(9):1324-1336. View abstract
  20. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer. 2018 08 01; 124(15):3210-3219. View abstract
  21. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 08; 65(8):e27077. View abstract
  22. Correction to: Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol. 2018 03; 48(3):454. View abstract
  23. Mid-Term Results After Sternal Reconstruction Using Titanium Plates: Is It Worth It to Plate? Ann Thorac Surg. 2018 06; 105(6):1640-1647. View abstract
  24. Imaging Optimization in Children. J Am Coll Radiol. 2018 03; 15(3 Pt A):440-443. View abstract
  25. Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol. 2018 01; 48(1):21-30. View abstract
  26. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017 Nov 07; 17(1):28. View abstract
  27. Liposuction for Swelling in Patients with Lymphedema. N Engl J Med. 2017 11 02; 377(18):1788-1789. View abstract
  28. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View abstract
  29. Role of imaging in the diagnosis of parotid infantile hemangiomas. Int J Pediatr Otorhinolaryngol. 2017 Nov; 102:61-66. View abstract
  30. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 01; 35(28):3215-3221. View abstract
  31. Operational and Dosimetric Aspects of Pediatric PET/CT. J Nucl Med. 2017 09; 58(9):1360-1366. View abstract
  32. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clin Cancer Res. 2017 Jun 15; 23(12):e46-e53. View abstract
  33. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clin Cancer Res. 2017 Jun 15; 23(12):e54-e61. View abstract
  34. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e68-e75. View abstract
  35. Pediatric Cancer Predisposition Imaging: Focus on Whole-Body MRI. Clin Cancer Res. 2017 Jun 01; 23(11):e6-e13. View abstract
  36. Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). View abstract
  37. Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. Pediatr Dev Pathol. 2018 Jan-Feb; 21(1):84-90. View abstract
  38. Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement. Pediatr Blood Cancer. 2017 Jul; 64(7). View abstract
  39. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 04; 64(4). View abstract
  40. Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. J Clin Endocrinol Metab. 2016 10; 101(10):3856-3862. View abstract
  41. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. Int J Pediatr Otorhinolaryngol. 2016 Jul; 86:218-23. View abstract
  42. Poor adherence to staging guidelines for children with malignant ovarian tumors. J Pediatr Surg. 2016 Sep; 51(9):1513-7. View abstract
  43. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution. Bioconjug Chem. 2015 Apr 15; 26(4):707-17. View abstract
  44. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51. View abstract
  45. Surveillance imaging in pediatric Hodgkin Lymphoma. Curr Hematol Malig Rep. 2013 Sep; 8(3):218-25. View abstract
  46. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6. View abstract
  47. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43. View abstract
  48. The radiographic appearance of split Blake drains: what you see is not necessarily what you get. Pediatr Radiol. 2013 Dec; 43(12):1573-6. View abstract
  49. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; 38(6):693-701. View abstract
  50. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5. View abstract
  51. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013 Jun; 9(3):252-60. View abstract
  52. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80. View abstract
  53. Reliable estimation of incoherent motion parametric maps from diffusion-weighted MRI using fusion bootstrap moves. Med Image Anal. 2013 Apr; 17(3):325-36. View abstract
  54. In vivo assessment of optimal b-value range for perfusion-insensitive apparent diffusion coefficient imaging. Med Phys. 2012 Aug; 39(8):4832-9. View abstract
  55. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20; 30(21):2635-40. View abstract
  56. Reliable assessment of perfusivity and diffusivity from diffusion imaging of the body. Med Image Comput Comput Assist Interv. 2012; 15(Pt 1):1-9. View abstract
  57. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62. View abstract
  58. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011 Aug; 13(8):910-5. View abstract
  59. Leukemia and lymphoma. Radiol Clin North Am. 2011 Jul; 49(4):767-97, vii. View abstract
  60. Adrenal cortical tumors in children: factors associated with poor outcome. J Pediatr Surg. 2011 Jun; 46(6):1201-7. View abstract
  61. Pediatric oncology and the future of oncological imaging. Pediatr Radiol. 2011 May; 41 Suppl 1:S172-85. View abstract
  62. Quantitative body DW-MRI biomarkers uncertainty estimation using unscented wild-bootstrap. Med Image Comput Comput Assist Interv. 2011; 14(Pt 2):74-81. View abstract
  63. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13. View abstract
  64. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011 Jan; 38(1):29-38. View abstract
  65. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. View abstract
  66. Synovial sarcoma in children: imaging features and common benign mimics. AJR Am J Roentgenol. 2010 Oct; 195(4):1026-32. View abstract
  67. Diagnostic errors in pediatric radiology. Pediatr Radiol. 2011 Mar; 41(3):327-34. View abstract
  68. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010 Jun; 45(6):1090-5. View abstract
  69. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol. 2010 Mar; 34(3):287-99. View abstract
  70. In utero diagnosis of congenital pyloric atresia in a single twin using MRI and ultrasound. J Pediatr Surg. 2009 Nov; 44(11):e21-4. View abstract
  71. The ALARA concept in pediatric oncology. Pediatr Radiol. 2009 Nov; 39(11):1142-6. View abstract
  72. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. View abstract
  73. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. J Clin Oncol. 2009 May 20; 27(15_suppl):10011. View abstract
  74. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7. View abstract
  75. A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses. Pediatr Radiol. 2008 Oct; 38(10):1099-104. View abstract
  76. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther. 2008; 24(2):119-25. View abstract
  77. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A. 2007 Oct 30; 104(44):17489-93. View abstract
  78. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82. View abstract
  79. 3D multidetector CT angiographic evaluation of extralobar pulmonary sequestration with anomalous venous drainage into the left internal mammary vein in a paediatric patient. Br J Radiol. 2006 Sep; 79(945):e99-102. View abstract
  80. The ischiopubic synchondrosis: changing appearance on PET/CT as a mimic of disease. Clin Nucl Med. 2006 Jul; 31(7):414-7. View abstract
  81. On the strong field dependence and nonlinear response to gadolinium contrast agent of proton transverse relaxation rates in dairy cream. Magn Reson Imaging. 2005 Jul; 23(6):757-64. View abstract
  82. Thymoma in a child: case report and review of the literature. Pediatr Surg Int. 2005 Jul; 21(7):548-51. View abstract
  83. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar; 57(3):445-52. View abstract
  84. Right ventricular pseudoaneurysm after modified Norwood procedure. Ann Thorac Surg. 2004 Oct; 78(4):e72-3. View abstract
  85. An integrated vector system for cellular studies of phage display-derived peptides. Anal Biochem. 2002 Sep 15; 308(2):364-72. View abstract
  86. Solitary osteosclerotic plasmacytoma: association with demyelinating polyneuropathy and amyloid deposition. Skeletal Radiol. 2001 Sep; 30(9):527-9. View abstract
  87. Chronic inflammatory pseudotumor arising in the hepatobiliary-pancreatic system: progressive multisystemic organ involvement in four patients. AJR Am J Roentgenol. 1999 Oct; 173(4):1049-54. View abstract
  88. Gene therapy: a primer for radiologists. Radiographics. 1998 Nov-Dec; 18(6):1343-72. View abstract
  89. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998 Sep 15; 161(6):2780-90. View abstract
  90. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998 Feb 15; 160(4):1618-26. View abstract
  91. CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J Immunol. 1997 Sep 01; 159(5):2154-60. View abstract
  92. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997; 15(5):213-26. View abstract
  93. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood. 1995 Dec 15; 86(12):4568-78. View abstract
  94. X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Clin Diagn Lab Immunol. 1995 Sep; 2(5):518-23. View abstract
  95. Addendum to SCID, interleukin-2, and the interleukin-2 receptor review. Blood. 1994 Jul 15; 84(2):667-8. View abstract
  96. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood. 1994 Feb 01; 83(3):626-35. View abstract
  97. Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2428-32. View abstract
  98. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J Immunol. 1993 Mar 01; 150(5):2046-55. View abstract
  99. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med. 1992 Aug 01; 176(2):531-41. View abstract
  100. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8. View abstract
  101. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer. 1992 Jan 15; 69(2):562-71. View abstract
  102. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med. 1990 Oct 01; 172(4):1101-14. View abstract
  103. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 1990 May 01; 50(9):2683-91. View abstract
  104. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother. 1989; 29(4):261-9. View abstract
  105. The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull N Y Acad Med. 1989 Jan; 65(1):93-110. View abstract